Sirius Medical secured funding to accelerate the commercial launch of the Sirius Pintuition System for cancer localization. This innovative system provides surgical oncologists with a highly precise, easy-to-use, and affordable solution that contributes to an improved hospital workflow.
Ambitious growth plans
The Dutch medical company has its roots in the Netherlands Cancer Institute and the University of Twente. The funding enables Sirius Medical to execute on its ambitious growth plans; delivering superior localization technology to our customers and developing our further pipeline of solutions.
For patients diagnosed with breast cancer, breast conserving surgery is the cornerstone of a curative approach. As diagnostics have rapidly improved over the past decades, surgeons are facing increasingly challenging procedures as they have to locate ever smaller and earlier-stage tumours. Until now, patient-unfriendly metal anchor wires were used as surgical localization devices to guide the surgeon.
Accurate and real-time feedback
Sirius Pintuition enables breast surgeons to accurately pinpoint the tumor location during surgery while optimizing hospital workflow. The Sirius Pintuition System is CE marked and FDA clearance is pending. The Sirius Pintuition seed can be placed up to 180 days before the surgery to mark a target within soft tissue. During surgery, the Sirius Pintuition Probe provides highly accurate, real-time feedback and directional guidance to the marked tissue.